Tech Center 1600 • Art Units: 1644 1646
This examiner grants 50% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17762685 | NOTCH RECEPTORS WITH MINIMAL LINKER | Non-Final OA | The Regents of the University of California |
| 18307309 | METHODS FOR SELECTING PATIENTS FOR TREATMENT WITH AN NGF ANTAGONIST | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 17602562 | HUMAN ANTIBODIES THAT BIND RET AND METHODS OF USE THEREOF | Final Rejection | Regeneron Pharmaceuticals, Inc. |
| 17421337 | EX VIVO ACTIVATED T-LYMPHOCYTIC COMPOSITIONS AND METHODS OF USING THE SAME | Non-Final OA | CHILDREN'S NATIONAL MEDICAL CENTER |
| 17627894 | CELL-TYPE SELECTIVE IMMUNOPROTECTION OF CELLS | Non-Final OA | UNIVERSITY OF ROCHESTER |
| 18020584 | SINGLE VARIABLE DOMAIN AND ANTIGEN BINDING MOLECULE BINDING BCMA | Non-Final OA | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. |
| 17758524 | TGF-BETA INHIBITORS AND USE THEREOF | Non-Final OA | SCHOLAR ROCK, INC. |
| 17757056 | NUCLEIC ACID ENCODING LILRB1-BASED CHIMERIC ANTIGEN RECEPTOR | Non-Final OA | A2 Biotherapeutics, Inc. |
| 17758116 | BCMA-DIRECTED CELLULAR IMMUNOTHERAPY COMPOSITIONS AND METHODS | Non-Final OA | Nkarta, Inc. |
| 17796148 | METHODS AND COMPOSITIONS FOR TREATING CANCER OR VIRAL INFECTION WITH A PLA2G2D ANTAGONIST | Final Rejection | Apeximmune Therapeutics Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy